ATM, radiation, and the risk of second primary breast cancer

References

• Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. Nat Methods. 7:248–249.
   PubMed Web of Science ®Google Scholar
• Andrade MA, Bork P. 1995. HEAT repeats in the Huntington’s disease protein. Nat Genet. 11:115–116.
   PubMed Web of Science ®Google Scholar
• Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. 1998. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet. 352:541.
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, et al. 2014. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 371:497–506.
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:499–506.
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. 2004. Initiating cellular stress responses. Cell. 118:9–17.
   PubMed Web of Science ®Google Scholar
• Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, et al. 2008. Variation of breast cancer risk among BRCA1/2 carriers. JAMA-J Am Med Assoc. 299:194–201.
   PubMed Web of Science ®Google Scholar
• Berkovich E, Monnat RJ, Kastan MB. 2008. Assessment of protein dynamics and DNA repair following generation of DNA double-strand breaks at defined genomic sites. Nat Protoc. 3:915–922.
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Haile RW, Stovall M, Boice JD, Jr., Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, et al. 2010. Radiation exposure, the ATM gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 102:475–483.
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Langholz B, Haile RW, Bernstein L, Thomas DC, Stovall M, Malone KE, Lynch CF, Olsen JH, Anton-Culver H, et al. 2004. Study design: evaluating gene-environment interactions in the etiology of breast cancer – the WECARE study. Breast Cancer Res. 6:R199–214.
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Teraoka S, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, Diep AT, Jansen L, Atencio DR, Olsen JH, et al. 2003. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat. 21:542–550.
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, et al. 2006. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T > G and c.1066-6T > G (IVS10-6T > G) from the Breast Cancer Family Registry. Hum Mutat. 27:1122–1128.
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Thompson WD, Risch N, Holford TR. 1992. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 136:925–936.
   PubMed Web of Science ®Google Scholar
• Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, et al. 2008. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 100:32–40.
   PubMedGoogle Scholar
• Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. 1992. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 326:781–785. Mar 19Epub 1992/03/29.
   PubMed Web of Science ®Google Scholar
• Borg A, Haile RW, Malone KE, Capanu M, Diep A, Torngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, et al. 2010. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat. 31:E1200–1240.
   PubMed Web of Science ®Google Scholar
• Bosotti R, Isacchi A, Sonnhammer EL. 2000. FAT: a novel domain in PIK-related kinases. Trends Biochem Sci. 25:225–227.
   PubMed Web of Science ®Google Scholar
• Brooks JD, John EM, Mellemkjaer L, Reiner AS, Malone KE, Lynch CF, Figueiredo JC, Haile RW, Shore RE, Group WSC, et al. 2012. Body mass index and risk of second primary breast cancer: the WECARE Study. Breast Cancer Res Treat. Jan131:571–580. Epub 2011/09/06.
   PubMed Web of Science ®Google Scholar
• Campeau PM, Foulkes WD, Tischkowitz MD. 2008. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 124:31–42.
   PubMed Web of Science ®Google Scholar
• Chen Y, Thompson W, Semenciw R, Mao Y. 1999. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 8:855–861.
   PubMed Web of Science ®Google Scholar
• Claus EB, Stowe M, Carter D, Holford T. 2003. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast. 12:451–456.
   PubMed Web of Science ®Google Scholar
• Concannon P, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, Teraoka SN, Diep TA, Jansen L, Atencio DP, Langholz B, et al. 2008. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res. 68:6486–6491.
   PubMed Web of Science ®Google Scholar
• Daniel JA, Pellegrini M, Lee BS, Guo Z, Filsuf D, Belkina NV, You Z, Paull TT, Sleckman BP, Feigenbaum L, et al. 2012. Loss of ATM kinase activity leads to embryonic lethality in mice. J Cell Biol. 198:295–304.
   PubMed Web of Science ®Google Scholar
• Donovan AJ. 1990. Bilateral breast cancer. Surg Clin North Am. 70:1141–1149.
   PubMed Web of Science ®Google Scholar
• Enns L, Rasouli-Nia A, Hendzel M, Marples B, Weinfeld M. 2015. Association of ATM activation and DNA repair with induced radioresistance after low-dose irradiation. Radiat Prot Dosimetry. 166:131–136.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et al. 2015. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43:D805–D811.
   PubMed Web of Science ®Google Scholar
• Gao X, Fisher SG, Emami B. 2003. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 56:1038–1045.
   PubMed Web of Science ®Google Scholar
• Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, Ersoy F, Foroud T, Jaspers NGJ, Lange K, et al. 1988. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 336:577–580.
   PubMed Web of Science ®Google Scholar
• Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K. 1991. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore). 70:99–117.
   PubMed Web of Science ®Google Scholar
• Gatti RA, Tward A, Concannon P. 1999. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 68:419–423.
   PubMed Web of Science ®Google Scholar
• Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, Zelicksson G, Friedman E. 2000. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer. 36:983–986.
   PubMed Web of Science ®Google Scholar
• Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. 2010. ATM activation by oxidative stress. Science. 330:517–521.
   PubMed Web of Science ®Google Scholar
• Helgason H, Rafnar T, Olafsdottir HS, Jonasson JG, Sigurdsson A, Stacey SN, Jonasdottir A, Tryggvadottir L, Alexiusdottir K, Haraldsson A, et al. 2015. Loss-of-function variants in ATM confer risk of gastric cancer. Nat Genet. 47:906–910.
   PubMed Web of Science ®Google Scholar
• Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, Stovall M, van Leeuwen FE. 2008. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 26:5561–5568.
   PubMed Web of Science ®Google Scholar
• Horn PL, Thompson WD. 1988. Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors. Cancer. 62:412–424.
   PubMed Web of Science ®Google Scholar
• Horn PL, Thompson WD, Schwartz SM. 1987. Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. J Chronic Dis. 40:1003–1011.
   PubMedGoogle Scholar
• Jaspers NG, Gatti RA, Baan C, Linssen PC, Bootsma D. 1988. Genetic complementation analysis of ataxia telangiectasia and Nijmegen breakage syndrome: a survey of 50 patients. Cytogenet Cell Genet. 49:259–263.
   PubMedGoogle Scholar
• Kanu N, Behrens A. 2007. ATMIN defines an NBS1-independent pathway of ATM signalling. EMBO J. 26:2933–2941.
   PubMed Web of Science ®Google Scholar
• Kelsey JL, Gammon MD, John EM. 1993. Reproductive factors and breast cancer. Epidemiol Rev. 15:36–47.
   PubMed Web of Science ®Google Scholar
• Knight JA, Bernstein L, Largent J, Capanu M, Begg CB, Mellemkjaer L, Lynch CF, Malone KE, Reiner AS, Liang X, et al. 2009. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women’s Environmental Cancer and Radiation Epidemiology Study. Am J Epidemiol. 169:962–968.
   PubMed Web of Science ®Google Scholar
• Kumar P, Henikoff S, Ng PC. 2009. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 4:1073–1081.
   PubMed Web of Science ®Google Scholar
• Largent JA, Capanu M, Bernstein L, Langholz B, Mellemkaer L, Malone KE, Begg CB, Haile RW, Lynch CF, Anton-Culver H, et al. 2007. Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiol Biomarkers Prev. 16:906–911.
   PubMed Web of Science ®Google Scholar
• Lavin MF. 2008. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. Oct9:759–769. Epub 2008/09/25.
   PubMed Web of Science ®Google Scholar
• Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O’Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. 2016. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 536:285–291.
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Porter PL, Tang MT, Malone KE. 2009. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. JCO. 27:5312–5318.
   PubMed Web of Science ®Google Scholar
• Li CI, Malone KE, Porter PL, Daling JR. 2003. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer. 89:513–518.
   PubMed Web of Science ®Google Scholar
• Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, et al. 2010. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 28:2404–2410.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, et al. 2007. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 316:1160–1166.
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Dahl C, Olsen JH, Bertelsen L, Guldberg P, Christensen J, Borresen-Dale AL, Stovall M, Langholz B, Bernstein L, et al. 2008. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br J Cancer. 98:728–733.
   PubMed Web of Science ®Google Scholar
• Murnane JP, Painter RB. 1982. Complementation of the defects of DNA synthesis in irradiated and unirradiated ataxia-telangiectasia cells. Proc Natl Acad Sci USA. 79:1960–1963.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Yasui Y, Saito N, Tachibana A, Komatsu K, Ishizaki K. 2006. DNA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation. Radiat Res. 165:277–282.
   PubMed Web of Science ®Google Scholar
• Ojima M, Ban N, Kai M. 2008. DNA double-strand breaks induced by very low X-ray doses are largely due to bystander effects. Radiat Res. 170:365–371.
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Celeste A, Difilippantonio S, Guo R, Wang W, Feigenbaum L, Nussenzweig A. 2006. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature. 443:222–225.
   PubMed Web of Science ®Google Scholar
• Peto J, Mack TM. 2000. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 26:411–414.
   PubMed Web of Science ®Google Scholar
• Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, et al. 2000. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. JCO. 18:3360–3369.
   PubMed Web of Science ®Google Scholar
• Prior P, Waterhouse JA. 1978. Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. Br J Cancer. 37:620–634.
   PubMed Web of Science ®Google Scholar
• Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, et al. 2006. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 38:873–875.
   PubMed Web of Science ®Google Scholar
• Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, et al. 2012. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2:41–46.
   PubMed Web of Science ®Google Scholar
• Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, et al. 1998. BRCA-associated breast cancer in young women. JCO. 16:1642–1649.
   PubMed Web of Science ®Google Scholar
• Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, et al. 1999. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 91:2112–2117.
   PubMedGoogle Scholar
• Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, et al. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1749–1753.
   PubMed Web of Science ®Google Scholar
• Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P. 2000. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA. 97:2773–2778.
   PubMed Web of Science ®Google Scholar
• Seidel JJ, Anderson CM, Blackburn EH. 2008. A novel Tel1/ATM N-terminal motif, TAN, is essential for telomere length maintenance and a DNA damage response. Mol Cell Biol. 28:5736–5746.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, Bedenham T, Bradwell AR, Easton DF, Lennox GG, et al. 1998. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet. 62:334–345.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Taylor AM, Yuille MR, Vorechovsky I. 2001. Recurrent ATM mutations in T-PLL on diverse haplotypes: no support for their germline origin. Blood. 97:1517–1518.
   PubMed Web of Science ®Google Scholar
• Steinmann D, Bremer M, Rades D, Skawran B, Siebrands C, Karstens JH, Dork T. 2001. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer. 85:850–858.
   PubMed Web of Science ®Google Scholar
• Stiff T, Walker SA, Cerosaletti K, Goodarzi AA, Petermann E, Concannon P, O’Driscoll M, Jeggo PA. 2006. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J. 25:5775–5782.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Döhner H. 1997. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 3:1155–1159.
   PubMed Web of Science ®Google Scholar
• Stoppa-Lyonnet D, Lauge A, Sigaux F, Stern MH. 2000. No germline ATM mutation in a series of 16T-cell prolymphocytic leukemias. Blood. 96:374–376.
   PubMed Web of Science ®Google Scholar
• Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, Sigaux F, Stern MH. 1998. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 91:3920–3926.
   PubMed Web of Science ®Google Scholar
• Stovall M, Smith SA, Langholz BM, Boice JD Jr, Shore RE, Andersson M, Buchholz TA, Capanu M, Bernstein L, Lynch CF, et al. 2008. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys. 72:1021–1030.
   PubMed Web of Science ®Google Scholar
• Swift M, Chase CL, Morrell D. 1990. Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet. 46:21–27.
   PubMed Web of Science ®Google Scholar
• Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. 1986. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 39:573–583.
   PubMed Web of Science ®Google Scholar
• Swift M, Reitnauer PJ, Morrell D, Chase CL. 1987. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 316:1289–1294.
   PubMed Web of Science ®Google Scholar
• Swift M, Sholman L, Perry M, Chase C. 1976. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res. 36:209–215.
   PubMed Web of Science ®Google Scholar
• Taylor AMR, Harnden DG, Arlett CF, Harcourt SA, Lehmann AR, Stevens S, Bridges BA. 1975. Ataxia-telangiectasia: a human mutation with abnormal radiation sensitivity. Nature. 258:427–429.
   PubMed Web of Science ®Google Scholar
• Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L, et al. 2012. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat. 33:674–680.
   PubMed Web of Science ®Google Scholar
• Uziel T, Savitsky K, Platzer M, Ziv Y, Helblitz T, Nehls M, Boehm T, Rosenthal A, Shiloh Y, Rotman G. 1996. Genomic organization of the ATM gene. Genomics. 33:317–320.
   PubMed Web of Science ®Google Scholar
• Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, Tilanus-Linthorst MM, Wagner A, Devilee P, Halley DJ, et al. 1999. Survival in hereditary breast cancer associated with germline mutations of BRCA2. JCO. 17:3396–3402.
   PubMed Web of Science ®Google Scholar
• Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. 2000. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 83:384–386.
   PubMed Web of Science ®Google Scholar
• Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, et al. 1998. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 351:316–321.
   PubMed Web of Science ®Google Scholar
• Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC, Foroni L, Hammarstrom L, Webster AD, Yuille MA. 1997. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. NatGenet. 17:96–99.
   Google Scholar
• Yajima H, Lee KJ, Zhang S, Kobayashi J, Chen BP. 2009. DNA double-strand break formation upon UV-induced replication stress activates ATM and DNA-PKcs kinases. J Mol Biol. 385:800–810.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Wang Y, Jiang W, Liu X, Dubois RL, Lin CS, Ludwig T, Bakkenist CJ, Zha S. 2012. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J Cell Biol. 198:305–313.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Wang J, Sprinzen L, Xu J, Haddock CJ, Li C, Lee BJ, Loredan DG, Jiang W, Vindigni A, et al. 2016. Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. eLife. Jun 15;5. doi: 10.7554/eLife.14709.
   Web of Science ®Google Scholar